Browse by author
Lookup NU author(s): Dr Lucy Crossman,
Professor Stephen O'Brien
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Since its introduction 5 years ago, imatinib mesylate has shown remarkable efficacy in treating patients with chronic myeloid leukaemia. Here we shall review the clinical results seen with imatinib at all stages of the disease, current views on the best way to monitor patients' responses and potential ways of predicting response to treatment. We shall also briefly cover the reasons why quiescent stein cells pose a theoretical threat to successful treatment. (C) 2003 Elsevier Ltd. All rights reserved.
Author(s): Crossman LC, O'Brien SG
Publication type: Article
Publication status: Published
Journal: Leukemia Research
Issue: Supplement 1
ISSN (print): 0145-2126
ISSN (electronic): 1873-5835
Notes: Issue title: The New Era of Imatinib Mesylate
Altmetrics provided by Altmetric